// App-Quantinova.ai

313.0 : An updated retrospective review of the safety and efficacy of sorafenib for recurrent hepatocellular carcinoma post-liver transplantation.

Researchers

Presenter

  • Sophie Feng

Principal Investigators

  • Nazanin Fallah-Rad

  • Yanshuo Cao

  • Jennifer J. Knox

  • Raymond Woo-Jun Jang

  • Neesha C. Dhani

  • Gonzalo Sapisochin

  • David Grant

  • Paul D Greig

  • Leslie Lilly

  • Andre Gorgen

  • Eric Xueyu Chen

Medical Centers

  • Redcliffe Hospital, Brisbane Queensland, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

  • Toronto Western Hospital, Toronto, ON, Canada

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

Locations

  • Australia

  • Canada

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved